78056-28-7 Usage
Uses
Used in Pharmaceutical Synthesis:
AKOS BC-0240 is used as an intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs and medicinal compounds.
Used in Organic Compound Synthesis:
AKOS BC-0240 is utilized as an intermediate in the synthesis of various organic compounds, highlighting its versatility in chemical reactions and its potential to create a range of products.
Used in Biological Research:
AKOS BC-0240 is employed as a potential inhibitor in biological processes, serving as a tool in research to understand its effects and mechanisms, which could lead to advancements in certain therapeutic areas.
Used in Industrial Processes:
AKOS BC-0240 is applied in industrial processes due to its solubility and reactivity, making it a valuable component in the production of various chemical and pharmaceutical products.
Check Digit Verification of cas no
The CAS Registry Mumber 78056-28-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,0,5 and 6 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 78056-28:
(7*7)+(6*8)+(5*0)+(4*5)+(3*6)+(2*2)+(1*8)=147
147 % 10 = 7
So 78056-28-7 is a valid CAS Registry Number.
InChI:InChI=1S/C11H19N/c1-10-3-8-2-9(4-10)6-11(12,5-8)7-10/h8-9H,2-7,12H2,1H3
78056-28-7Relevant academic research and scientific papers
Structure-Anti-Parkinson Activity Relationships in the Aminoadamantanes. Influence of Bridgehead Substitution
Henkel, James G.,Hane, Jeffrey T.,Gianutsos, Gerald
, p. 51 - 56 (2007/10/02)
A limited series of bridgehead alkyl-, dialkyl- and trialkyl-substituted amantadines was synthesized and tested for potential anti-Parkinson activity as dopamine (DA) agonists.The compounds were evaluated using a battery of three murine bioassays, including stimulation of locomotor activity, induction of circling in animals with unilateral striatal lesions, and reversal of reserpine/α-methyltyrosine induced akinesia.Apparent mechanistic differences were seen between the methyl-substituted series and the ethyl-substituted series.While activities in both series increase with increasing liphophilicity, the methyl series (1b-d), as well as amantadine itself (1a) exhibits only indirect DA agonist activity, as evidenced by ipsilateral rotation in the circling model and no significant difference from control in reversal of akinesia.The ethyl series (1e,f) exhibits weak but reprodicible direct DA agonist activity, as shown by contralateral rotation in the circling assay for 1e and reversal of akinesia by 1e and 1f.The 3-n-propyl derivative (1g) was devoid of any DA agonist activity.
